Ask AI
Do it better in CRM disease

CE / CME

Do It Better: Effective Strategies for Implementing Evidence-Based, Patient-Centered Care in Cardio-Renal-Metabolic Disease

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: November 05, 2025

Expiration: November 04, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following presents a common reason for the delayed or lack of use of GDMT in patients with HF?

2.

Which of the following statements best reflects the current evidence regarding the early initiation and long-term use of SGLT2 inhibitors in patients with HF, regardless of EF?

3.

A 62-yr-old man with type 2 diabetes, hypertension, and stage 3 chronic kidney disease (eGFR 42 mL/min/1.73 m2, albuminuria) presents for follow-up. He also has a history of heart failure with preserved ejection fraction. His A1C is 7.8% on metformin 500 mg BID and semaglutide 2.0 mg weekly. According to current guideline-directed therapy, which of the following is the most appropriate next step to reduce progression of kidney disease and lower cardiovascular risk?